

**ITEM 1  
COVER PAGE**

**Part 2B OF FORM ADV: FIRM BROCHURE**

# **Arcoda Capital Management, LP**

90 Park Avenue, 5th Floor  
New York, New York 10016  
212-848-0603  
[www.arcodacapital.com](http://www.arcodacapital.com)

**February 2012**

## **Brochure Supplement**

Michael Meyers  
Telephone: 212-848-0602  
Facsimile: 212-848-0755  
Electronic Mail: [mmeyers@arcodacapital.com](mailto:mmeyers@arcodacapital.com)

This brochure provides information about Michael Meyers that supplements the Arcoda Capital Management, LP and Arcoda Group LLC (collectively, “**Arcoda**,” or “**we**,” or “**us**,” or “**our**”) brochure. You should have received a copy of the brochure. If you did not receive a copy of the brochure or if you have any questions about the contents of this supplement, please contact Karen Weiss at 212-848-0603 or [kweiss@arcodacapital.com](mailto:kweiss@arcodacapital.com).

## **ITEM 2**

### **EDUCATIONAL BACKGROUND AND BUSINESS EXPERIENCE**

Michael Meyers, M.P.H. is the Chief Executive Officer and Chief Investment Officer of Arcoda. Michael was born in 1968 and has enjoyed a 20 year career in healthcare. He co-founded Arcoda in 2007. Between October 2006 and April 2007, Mr. Meyers was a Partner and Portfolio Manager of GoldenTree Asset Management LP. Between 2002 and 2006, Mr. Meyers was a founding Managing Partner, Portfolio Manager and Sector Head of Healthcare of Trivium Capital Management LLC. Between 2000 and 2003, Mr. Meyers was a Managing Director, Partner and Director of Global Biomedical Partners (“**GBP**”), a life sciences venture capital firm that was located in New York and Zurich, Switzerland. GBP managed International BM Biomedicine Holdings AG, which was acquired by HBM Bioventures, a Swiss based venture capital fund. Between 1997 and 2000, Mr. Meyers was a Director, Biotechnology and Pharmaceutical Investment Banking at Merrill Lynch & Co. Prior to that Mr. Meyers was Vice President, Healthcare Investment Banking at Cowen & Company. Prior to Cowen, Mr. Meyers was Special Assistant to the Chief Executive Officer of St. Barnabas Hospital and its affiliates.

Mr. Meyers began his career as a Biotechnology and Medical Device Research Analyst at Hambrecht & Quist. Mr. Meyers holds an M.P.H. in Health Policy and Management from Columbia University and an A.B. in Biology from Brandeis University in Massachusetts.

## **ITEM 3**

### **DISCIPLINARY INFORMATION**

There have been no legal or disciplinary events material to a client’s or prospective client’s evaluation of a supervised person.

## **ITEM 4**

### **OTHER BUSINESS ACTIVITIES**

No supervised person is actively engaged in any investment-related business or occupation, including if the supervised person is registered, or has an application pending to register, as a broker-dealer, registered representative of a broker-dealer, futures commission merchant (“**FCM**”), commodity pool operator (“**CPO**”), commodity trading advisor (“**CTA**”), or an associated person of an FCM, CPO, or CTA.

No supervised person is actively engaged in any business or occupation for compensation not discussed above that provides a substantial source of the supervised person’s income or are any substantive amount of the supervised person’s time.

## **ITEM 5 ADDITIONAL COMPENSATION**

No supervised person receives an economic benefit for providing non-*clients* advisory services.

## **ITEM 6 SUPERVISION**

Due to the size of our staff, supervision is not formalized, beyond the fact that the Mr. Meyers has overall authority of the Arcoda's operations and sole investment decision-making authority. We conduct a high level review of each of the Client Account portfolios daily, as part of the ongoing portfolio management activities. We also conduct more broad-based, strategic reviews weekly, in which the portfolio manager as well as our Chief Financial Officer, analysts and traders participate. Each employee must avoid any activity or relationship that may reflect unfavorably on us as a result of a possible conflict of interest, the appearance of such a conflict, the improper use of confidential information, or the appearance of any impropriety. The chief compliance officer monitors various aspects of the Firm's activities for compliance with the Firm's policies and applicable law.

Our Chief Compliance Officer, Karen Weiss, may be contacted regarding Mr. Meyers's advisory activities on our behalf, and can be reached at 212-848-0603 or [kweiss@arcodacapital.com](mailto:kweiss@arcodacapital.com).